Hair relaxer (chemical hair straightener) settlement values are widely projected from about $100,000 to $1,750,000 per plaintiff, with the largest amounts for women diagnosed with uterine or endometrial cancer who underwent a hysterectomy. This hair relaxer uterine cancer settlement calculator estimates a payout from your cancer-severity tier, medical bills, lost wages, and a pain-and-suffering multiplier. Thousands of claims are consolidated in the federal hair relaxer multidistrict litigation (MDL 3060) before the U.S. District Court for the Northern District of Illinois. Use the calculator, then read how the science, the MDL, and damages combine to set hair relaxer payouts.
The lawsuits allege that chemical hair relaxers and straighteners — used heavily and frequently by Black women — contain endocrine-disrupting chemicals, including phthalates and compounds that can release formaldehyde, and that manufacturers failed to warn of an increased risk of uterine cancer, endometriosis, and uterine fibroids. The litigation gained momentum after a 2022 National Institutes of Health (NIH) Sister Study reported higher uterine-cancer rates among frequent relaxer users.
No global hair relaxer settlement has been finalized as of 2026 — trials are expected in 2027 — so projected values come from a tier framework combined with conventional injury-damage math. The tier reflects the diagnosis and treatment, while the dollar amount within a tier depends on years of product use, age, and economic losses. The calculator follows this approach:
Hair Relaxer Estimate = Injury-Tier Anchor + Economic Damages (medical + lost wages) + Pain & Suffering (medical × multiplier)
The strongest cases involve uterine (endometrial) cancer requiring a hysterectomy, which carries the highest projected tier. Ovarian cancer, severe endometriosis, and uterine fibroids requiring surgery fall into middle and lower tiers. Long-term, frequent use of relaxers — especially beginning in adolescence — strengthens causation and raises a claim within its tier.
The 2022 NIH Sister Study, published in the Journal of the National Cancer Institute, followed roughly 33,000 women and found that those who used chemical hair straighteners more than four times in the prior year had over double the uterine-cancer risk of non-users. That epidemiology anchors the litigation. The table summarizes the tiers most often discussed.
| Tier | Condition | Projected Range |
|---|---|---|
| Tier 1 | Uterine / endometrial cancer with hysterectomy | ~$300,000 – $1,750,000 |
| Tier 2 | Uterine cancer, organs preserved | ~$150,000 – $600,000 |
| Tier 3 | Ovarian cancer / severe endometriosis | ~$75,000 – $300,000 |
| Tier 4 | Uterine fibroids requiring surgery | ~$25,000 – $100,000 |
Federal hair relaxer cases are centralized in MDL 3060 before Judge Mary Rowland in the Northern District of Illinois, with L'Oréal and other manufacturers as defendants. As in other mass torts, the court is managing discovery and preparing bellwether trials — representative cases tried first to gauge how juries value the injuries. Bellwether outcomes typically establish the settlement matrix that resolves the remaining tens of thousands of claims. As of 2026 the litigation remained in pretrial stages, with trials anticipated in 2027.
Suppose a woman diagnosed with uterine cancer who underwent a hysterectomy (Tier 1) has $90,000 in medical bills, $50,000 in lost wages, and a pain-and-suffering multiplier of 4. The calculator computes economic damages of $140,000 and pain-and-suffering of $360,000 (medical × 4), for a formula value of $500,000 within the Tier 1 band, displaying a likely range of roughly $275,000 to $750,000. A Tier 4 claimant with fibroids, $20,000 in medical bills, and a multiplier of 2 would land near the lower anchor. These figures illustrate how diagnosis and damages drive the estimate.
Under IRS Publication 4345, compensatory damages for a personal physical injury or physical sickness — including uterine cancer — are generally excluded from taxable income. Interest and punitive damages are taxable, and amounts allocated to non-physical claims may be treated differently. Confirm the tax treatment of your specific recovery with a qualified tax professional.
A hair relaxer claim begins with case screening — confirming a qualifying diagnosis (most often uterine or endometrial cancer), documenting a history of relaxer use, and verifying the statute of limitations. The case is then filed into MDL 3060 in the Northern District of Illinois, joining thousands of others for coordinated discovery. Because trials are expected in 2027, the litigation is still building its evidentiary record, including the epidemiology connecting frequent relaxer use to uterine cancer. Bellwether trials will test how juries value the injuries, and a settlement matrix typically follows. Claimants are then tiered by diagnosis and circumstances, and payments are distributed over time, net of fees, costs, and liens. This is a multi-year process, not a quick payout.
Hair relaxer cases are usually handled on contingency, with the attorney earning a percentage of any recovery — commonly 33% to 40% — plus reimbursement of case costs such as expert and filing fees. Health insurers, Medicare, or Medicaid may assert liens for cancer-treatment bills they paid, and those liens are satisfied from the settlement, though they can often be negotiated lower. The number this calculator produces is a gross value; your net is what remains after fees, costs, and liens. For example, on a $500,000 gross settlement with a 38% fee, $20,000 in costs, and a $30,000 negotiated lien, the net to the claimant would be roughly $240,000. Request a written breakdown from your attorney.
Certain facts can lower a hair relaxer estimate. Infrequent or short-term product use weakens the causal link, since the NIH study tied risk to frequent use. A strong family history of uterine cancer, or other recognized risk factors, gives defendants an alternative-cause argument. A diagnosis outside the core conditions (for example, fibroids alone rather than uterine cancer) moves a claim to a lower tier. Difficulty identifying the specific relaxer brands used can also complicate the claim. And because no settlement matrix existed as of 2026, with trials expected in 2027, all values remain projections that depend on the bellwether outcomes and the science the court accepts. An honest attorney will assess how these factors apply to your case.
This hair relaxer uterine cancer settlement calculator is intended for women who used chemical hair relaxers or straighteners — often beginning in childhood or adolescence and continuing for years — and were later diagnosed with uterine or endometrial cancer, ovarian cancer, severe endometriosis, or uterine fibroids requiring surgery. It is also useful for family members pursuing a claim on behalf of a loved one who has passed away from uterine cancer. Because the litigation has disproportionately affected Black women, who use these products most frequently, the tool aims to give that community a clear, respectful way to understand how the claims are valued. Anyone unsure whether their diagnosis or usage history qualifies should treat the calculator as a starting point and seek a free case review.
The essentials of hair relaxer settlements are straightforward. The diagnosis sets the tier, with uterine cancer requiring a hysterectomy anchoring the highest values and fibroids anchoring lower ones. Frequency and duration of use drive causation, because the 2022 NIH Sister Study tied the elevated risk specifically to frequent use. No settlement matrix existed as of 2026, with trials expected in 2027, so all numbers are projections tied to the MDL 3060 bellwether process. The gross estimate is reduced by attorney fees, costs, and liens to reach your net. And deadlines vary by state, so acting promptly preserves your claim. Use the calculator to understand the framework, then let an attorney evaluate your specific diagnosis and product-use history.
Legal analysts commonly project hair relaxer settlement values from roughly $100,000 to $1,750,000, with the highest amounts for uterine or endometrial cancer requiring a hysterectomy and lower amounts for fibroids or endometriosis. No global settlement had been finalized as of 2026, with trials expected in 2027, so these are projections based on the tier framework and bellwether expectations in MDL 3060. Actual value depends on diagnosis, frequency of use, medical bills, and lost wages.
A 2022 NIH Sister Study, published in the Journal of the National Cancer Institute, followed about 33,000 women and found that frequent users of chemical hair straighteners (more than four times in the prior year) had over double the uterine-cancer risk of non-users. Researchers point to endocrine-disrupting chemicals such as phthalates and formaldehyde-releasing compounds. That epidemiology is the scientific foundation of the lawsuits.
Generally, women who used chemical hair relaxers or straighteners and were later diagnosed with uterine (endometrial) cancer, ovarian cancer, endometriosis, or uterine fibroids may qualify. Frequent, long-term use strengthens the claim. An attorney evaluates your product-use history, diagnosis, and timeline against the litigation criteria and your state's statute of limitations.
MDL 3060 is the federal hair relaxer multidistrict litigation centralized before Judge Mary Rowland in the U.S. District Court for the Northern District of Illinois, with L'Oreal and other manufacturers as defendants. It consolidates thousands of claims for coordinated pretrial proceedings and bellwether trials, which help set a framework for resolving the remaining cases.
As of 2026, MDL 3060 remained in pretrial stages, with bellwether trials anticipated in 2027. A global settlement framework usually follows the first bellwether verdicts. Mass-tort timelines often run several years; once a settlement matrix is negotiated, qualifying claimants typically receive payments in tiers over time.
Under IRS Publication 4345, compensatory damages for a physical sickness such as cancer are generally not taxable. Interest and punitive damages are taxable, and non-physical-injury portions may be treated differently. Confirm the treatment of your specific payout with a tax professional.
Receipts help but are not strictly required. Testimony about the brands, frequency, and duration of use, supported by any available receipts, photos, or salon records, can establish product use. Your medical records establish the diagnosis. An attorney helps assemble the proof needed for MDL 3060.